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General introduction, aim and outline of this thesis
Deep immune profiling of ovarian tumors, draining 
lymph nodes and circulating cells during neoadjuvant 
chemotherapy.
OncoImmunology (2020) 9(1):1-12*
CD103+ intraepithelial T cells in high-grade serous 
ovarian cancer are phenotypically diverse TCRαβ+ 
CD8αβ+ T cells that can be targeted for cancer 
immunotherapy.
Oncotarget (2016) 15;7(46):75130-75144
Minimal MHC-I expression after neoadjuvant 
chemotherapy in ovarian cancer is negatively 
associated with T-cell-dependent outcome.
OncoImmunology (2020) 9(1):1-12*
Targeted delivery of CD40L promotes restricted 
activation of antigen-presenting cells and induction 
of cancer cell death.
Molecular Cancer (2014) 13(1):85
Immune-humanized mice carrying patient-derived 









*Published as: Deep immune profiling of ovarian tumors identifies minimal MHC-I expression  
after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.  
Oncoimmunology (2020) 9(1):1-12.  
Summary, discussion, conclusion and future 
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